Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05287126 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
A Phase 2 study of Ulcerative Colitis, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 20
- Study locations
NCT05287126 is a Phase 2 study of Ulcerative Colitis that is actively recruiting participants, run by Pfizer. The registered enrollment target is 36 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT05287126, a Phase 2 study of Ulcerative Colitis, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to \< 18 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).
Conditions Studied
Interventions
- DRUG Etrasimod
Study Locations (20)
California
- Valley View Wellness Medical Center - Garden Grove
- Loma Linda Children's Hospital - Loma Linda
- Loma Linda University Clinical Trial Center - Loma Linda
- Loma Linda University Eye Institute - Loma Linda
- Loma Linda University Medical Center - Loma Linda
- Loma Linda University Pediatric Clinics - Loma Linda
- Loma Linda University Children's Hospital Pediatric Specialty Clinics - San Bernardino
- University of California San Francisco, - San Francisco
- University of California San Francisco - San Francisco
- University of California,San Francisco Pediatric ClinicalResearch Center (PCRC) - San Francisco
Arkansas
- Arkansas Children's (IP Address) - Little Rock
- Arkansas Children's - Little Rock
Michigan
- William Beaumont Hospitals Reference Laboratory - Royal Oak
- William Beaumont Hospital - Royal Oak
Ohio
- University Hospitals Cleveland Medical Center Rainbow Babies & Children's Hospital - Cleveland
- University Hospitals Cleveland Medical Center - Cleveland
Florida
- Arnold Palmer Hospital - Center for Digestive Health and Nutrition - Orlando
Illinois
- University of Chicago Medical Center - Chicago
Massachusetts
- Boston Children's Hospital - Boston
Texas
- Advance Clinical Trial PLLC - Abilene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-12-16 |
| Est. Completion | 2031-08-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05287126
The ClinicalTrials.gov registry entry for NCT05287126 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which Etrasimod is the first listed.
NCT05287126 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Arkansas, Michigan.
Frequently Asked Questions
What is clinical trial NCT05287126 about?
NCT05287126 is a clinical study titled "A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis". The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to \< 18 years of age). Participants who will complete the total 52-week treatment period will ha...
What is the current status of trial NCT05287126?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2022-12-16. Estimated completion is 2031-08-07.
What conditions does trial NCT05287126 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT05287126?
The interventions under investigation include: Etrasimod (DRUG).
Who is sponsoring clinical trial NCT05287126?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05287126 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
Treatment of UC With Novel Therapeutics
RECRUITING · Phase 2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.